Although antibodies, at the time of writing, still dominate the clinic, there is a definite shift in the drug development pipeline towards more "complex", next-generation molecules. The array of new formats for the NGB sector is bewildering. Any expression platform developed must therefore address general needs arising from such engineered proteins rather than the needs of a specific molecule type. It is likely that such an expression platform will actually comprise a toolbox of solutions for scientists to get the best chance of translating their idea into reality.
Content Type: Article
Download
Latest content

Latest briefing from the Knowledge Center